Clinical Study of the Use of Amino Acid Peritoneal Dialysate in Diabetic Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe People's Hospital of Gaozhou
About this trial
The study is a single center, open, prospective, self controlled clinical study. The patients with diabetes who are to be enrolled in peritoneal dialysis are to observe the changes of glycosylated hemoglobin relative to the baseline 90 days after using amino acid (15) peritoneal dialysis solution.
Eligibility criteria
Qualifiers
Type I or II diabetes patients aged 18 to 75 years (including 18 and 75 years), regardless of gender;
Stable peritoneal dialysis patients who have undergone peritoneal dialysis treatment for ≥ 3 months;
Use 3-5 bags of peritoneal dialysis solution daily;
6.0%<glycated hemoglobin (HbA1c) level ≤ 8.5%;
Disqualifiers
Peritonitis has occurred within the past 3 months;
Use Acodextrin peritoneal dialysis solution;
Individuals allergic to any component of amino acid (15) peritoneal dialysis fluid;
Serum urea level>38 mmol/l;
Trial design
Treatments tested in this trial
- Amino acid peritoneal dialysis solution
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
The People's Hospital of Gaozhou
Lead sponsor
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Collaborator
Source ClinicalTrials.gov